VCYT · Veracyte, Inc.
$55.65
+0.04 (+0.07%)
At close · Jul 28
Market Cap
$4.44B
Shares
79.79M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$55.65
Open$55.60
Day$54.72–56.63
52W$22.92–60.91
Avg vol 30d1.3M
Short int6.7M · 8.4% float · 6.8d
Short vol69%
Last earningsJul 30, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 6
Up next
Next earnings call
Jul 30, 2026
Scheduled
· this week
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+34%
above
Price vs 50-day avg
+7%
above
RSI (14)
49
neutral
MACD trend
Negative
52-week position
86%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−8%
trailing
6-month return
+46%
trailing
YTD return
+32%
this year
Relative strength
+38%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $52 › 200d $41 — 50d above 200d
Institutional flow
Accumulating
70 of 335 funds reported for Jun 30 · net +449.1K sh shares · +13 new
Insider flow
Distributing
Net -$9.9M over 90 days · 100% sells
Short interest
Falling
8.36% of float · ▼ -0.6% MoM · 6.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
335 holders — near 3-yr high, broad support
Squeeze score
87
high risk · 0–100
Fundamentals
Revenue growth
+16%
Y/Y
Gross margin
70%
expanding
EPS growth
+165%
Y/Y
Free cash flow
$126.6M
Valuation
P/E 51.5
rich
Balance sheet
$362.6M
net cash
Quant / Vol
risk profile
Volatility
60%
annualized · 1-yr
Max drawdown
−39%
past year
ATR
4.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 5, 2026
Total revenue
· 2026
Initiated
$582M – $592M
prior FY $517.15M
midpoint +13.5% Y/Y
Testing revenue
· 2026
Initiated
$570M – $580M
prior FY $517.15M
midpoint +11.2% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+34%
Bullish
Price vs 50-day avg
+7%
Bullish
RSI (14)
49
Neutral
MACD trend
Negative
Bearish
52-week position
86%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $52 › 200d $41 — 50d above 200d
Institutional flow
Accumulating
70 of 335 funds reported for Jun 30 · net +449.1K sh shares · +13 new
Insider flow
Distributing
Net -$9.9M over 90 days · 100% sells
Short interest
Falling
8.36% of float · ▼ -0.6% MoM · 6.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
335 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $23
Now $56 · 86%
52-wk high $61
vs 200-day avg +34%
vs 50-day avg +7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $42.8M | Q1 2026 | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 30.8% | Q1 2026 | — |
|
|
|||
| Afirma volume | 17,200 | Q1 2026 | — |
|
|
|||
| Cash from operations | $35.2M | Q1 2026 | — |
|
|
|||
| Decipher volume | 28,000 | Q1 2026 | — |
|
|
|||
| Testing volume | 45,248 | Q1 2026 | — |
|
|
|||
| Total volume | 47,615 | Q1 2026 | — |
|
|
|||
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VCYT
this stock
Veracyte, Inc.
|
$4.44B | +32.2% | +16.0% | 51.5 | 8.4% |
|
TMO
Thermo Fisher Scientific Inc.
|
$214.21B | -0.4% | +0.4% | 30.8 | 1.4% |
|
DHR
Danaher Corp /De/
|
$138.14B | -12.7% | +8.5% | 34.8 | 1.4% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.93B | -15.8% | +10.4% | 41.9 | 2.7% |
|
IQV
Iqvia Holdings Inc.
|
$40.55B | +7.8% | +41.6% | 30.2 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VCYT | -2.8% | -8.0% | +45.8% | -5.2% | +32.2% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -1.8% | -8.0% | +38.4% | -4.5% | +23.6% |
Key facts
CIK
1384101
CUSIP
92337F107
13F (30d)
62 filings
62 filers
Visit website
Investor relations